Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review

被引:50
|
作者
Rijks, Ester B. G. [1 ]
Bongers, Bart C. [1 ,5 ]
Vlemmix, Marloes J. G. [1 ,4 ]
Boot, Annemieke M. [6 ]
van Dijk, Atty T. H. [2 ]
Sakkers, Ralph J. B. [3 ]
van Brussel, Marco [1 ]
机构
[1] Wilhelmina Childrens Hosp, Child Dev & Exercise Ctr, NL-3508 AB Utrecht, Netherlands
[2] Wilhelmina Childrens Hosp, Dept Pediat, NL-3508 AB Utrecht, Netherlands
[3] Wilhelmina Childrens Hosp, Dept Orthoped, NL-3508 AB Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Clin Hlth Sci, Utrecht, Netherlands
[5] Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, Dept Epidemiol, Maastricht, Netherlands
[6] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Pediat Endocrinol Subdiv, Groningen, Netherlands
来源
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷 / 01期
关键词
Osteogenesis imperfecta; Child; Bisphosphonates; Fractures; Bone mineral density; INTRAVENOUS PAMIDRONATE TREATMENT; CONTROLLED-TRIAL; RISEDRONATE; PERSPECTIVES; OLPADRONATE; ASSOCIATION; ADOLESCENTS; ALENDRONATE; FRACTURES; COHORT;
D O I
10.1159/000381713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: To systematically assess contemporary knowledge regarding the effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta (OI). Methods: PubMed/MEDLINE, Embase, and Cochrane were searched for eligible articles up to June 2014. Studies eligible for inclusion were (randomized) controlled trials assessing the effects of BPs in children with OI. Methodological quality was assessed independently by 4 reviewers using the Cochrane Collaboration's tool for risk of bias. Results: Ten studies (519 children) were included. Four studies (40%) showed a low risk of bias. All studies investigating lumbar spine areal bone mineral density indicated a significant increase as a result of BP treatment. Most studies observed a significant decrease in fracture incidence. The most frequently reported adverse events were gastrointestinal complaints, fever, and muscle soreness. A significant decrease in (bone) pain due to BP treatment was observed in more than half of the studies. Most studies measuring urinary markers of bone resorption reported a significant decrease. The majority of studies with intravenous treatment showed a significant increase in lumbar projection area, whereas studies with oral treatment did not. Conclusions: Treatment with oral or intravenous BPs in children with OI results in an increase in bone mineral density and seems to be safe and well tolerated. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:26 / 42
页数:17
相关论文
共 50 条
  • [21] EFFECT OF DENOSUMAB ON CHILDREN WITH OSTEOGENESIS IMPERFECTA: A SYSTEMATIC REVIEW
    Zeng, J.
    Huang, Z.
    Li, G.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S326 - S327
  • [22] Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy
    Kashii, Masafumi
    Kanayama, Sadaaki
    Kitaoka, Taichi
    Makino, Takahiro
    Kaito, Takashi
    Iwasaki, Motoki
    Kubota, Takuo
    Yamamoto, Takehisa
    Ozono, Keiichi
    Yoshikawa, Hideki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2019, 37 (03) : 545 - 553
  • [23] Cyclic bisphosphonate therapy in osteogenesis imperfecta type V
    Fleming, F
    Woodhead, HJ
    Briody, JN
    Hall, J
    Cowell, CT
    Ault, J
    Kozlowski, K
    Sillence, DO
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2005, 41 (03) : 147 - 151
  • [24] Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta
    Biggin, A.
    Munns, C. F.
    CURRENT OSTEOPOROSIS REPORTS, 2017, 15 (05): : 412 - 418
  • [25] Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta
    A. Biggin
    C. F. Munns
    Current Osteoporosis Reports, 2017, 15 : 412 - 418
  • [26] Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapy
    D'Eufemia, Patrizia
    Finocchiaro, Roberto
    Zarnbrano, Anna
    Tetti, Martina
    Ferrucci, Valentina
    Celli, Mauro
    BIOMEDICINE & PHARMACOTHERAPY, 2007, 61 (04) : 235 - 240
  • [27] Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta
    Garganta, Melissa D.
    Jaser, Sarah S.
    Lazow, Margot A.
    Schoenecker, Jonathan G.
    Cobry, Erin
    Hays, Stephen R.
    Simmons, Jill H.
    BMC MUSCULOSKELETAL DISORDERS, 2018, 19
  • [28] Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial
    Hoyer-Kuhn, H.
    Franklin, J.
    Allo, G.
    Kron, M.
    Netzer, C.
    Eysel, P.
    Hero, B.
    Schoenau, E.
    Semler, O.
    JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 2016, 16 (01) : 24 - 32
  • [29] IV bisphosphonate therapy in children under 36 months of age with osteogenesis imperfecta.
    DiMeglio, LA
    Ford, L
    McClintock, C
    Peacock, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S382 - S382
  • [30] Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta
    Melissa D. Garganta
    Sarah S. Jaser
    Margot A. Lazow
    Jonathan G. Schoenecker
    Erin Cobry
    Stephen R. Hays
    Jill H. Simmons
    BMC Musculoskeletal Disorders, 19